Stephen Waterman Joins PharmaVentures

OXFORD, England, October 18, 2012 /PRNewswire/ --

PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing Pharmaventures' corporate finance capabilities and offerings to the global healthcare and investment communities.

Fintan Walton, PhD, PharmaVentures' Chief Executive Office, says: "We are delighted to welcome Stephen to PharmaVentures. Stephen has an impressive track record in investment banking and he brings a wealth of experience in private and public markets that will assist our clients with their deal making and Stephen's addition to PharmaVentures will therefore be of great benefit."

Stephen has previously worked with WG Partners, Matrix Corporate Capital, Elixir Securities, Commerzbank, Teather & Greenwood and Evaluate Pharma Plc. He has a BSc from Nottingham University and PhD from Cambridge University.

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more http://www.pharmaventures.com

Our services include:

• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 21st year, PharmaVentures is based in Oxford, UK, and employs over 17 people.

For further information, contact:

Dr Fintan Walton
CEO
PharmaVentures Ltd
+44-1865-332700
[email protected]

SOURCE PharmaVentures